



ASX release

11 January 2018

## **AtCor Medical and PhysioAge Systems Announce Multi-Practice Supply Agreement**

### ***New Practices in the PhysioAge Health Program Now Have Access to Arterial Stiffness Assessments with AtCor's Proven SphygmoCor® Technology***

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of SphygmoCor® for advanced hypertension management, today announced that it has entered into a multi-year supply agreement with PhysioAge Systems, LLC, a leader in the use of biomarkers of aging and personalised health analytics. Participating practices will now be able to offer noninvasive arterial stiffness measurements, as provided by SphygmoCor, one of the important biomarkers of physiological age. Arterial stiffness has become a critical biomarker in aging and a key driver of the risk for hypertension and cardiovascular disease.

The two year agreement will streamline the integration of SphygmoCor into the PhysioAge Program, making it more accessible to participating practices. Up to 100 new PhysioAge sites are forecast to install AtCor's SphygmoCor in calendar year 2018 - with eleven units sold in December 2017.

Joseph Raffaele, MD, co-founder of PhysioAge Medical Group and PhysioAge Systems said: "I have been using SphygmoCor for years as part of our 'PhysioAge Composite,' a set of biomarkers designed to determine a patient's physiological age [as opposed to chronological age]. We are pleased to now have an agreement in place that simplifies access to this important technology and supports our ambitious practice growth objectives. Participating practices will now be able to assess arterial age, help patients take preventative action, and quickly determine if interventions have been effective."

Craig Cooper, AtCor Medical CEO commented: "As the US healthcare system continues to evolve and patients take greater control of their own health, integrative and preventive medicine is becoming a significant market segment for our hypertension and cardiovascular diagnostic systems. We have enjoyed working with Dr. Raffaele and his team at PhysioAge in the past and we could not be more pleased to formalise and expand this important relationship going forward."

### **About PhysioAge Systems and Dr. Joseph Raffaele**

PhysioAge Systems was founded in 2008 by Joseph Raffaele, M.D., Jochen Kumm, PhD., and Jerry Fortunato, MBA who together developed a proprietary concept called the 'PhysioAge Composite' - a set of biomarkers designed to determine the *physiological* as opposed to *chronological* age of a subject patient.

The concept for PhysioAge was originally conceived in 2003 when Dr. Raffaele started looking at various validated biomarkers of aging to determine which would best capture the functioning of a subject's major organ systems relative to the average optimal youthful state. The founders then developed a web-based system to collect the biomarker data and generate physiological ages. Today, PhysioAge® services physician clients in four countries. As CEO of PhysioAge, Dr. Raffaele developed the specific combination of biomarkers currently in use and has worked with Dr. Kumm to develop 'The PhysioAge®Composite' as well as individual "age biomarkers" including CardioAge®, PulmoAge®, NeuroAge®, CutoAge®, ImmunoAge®, and TelomerAge®.

Dr. Raffaele co-founded PhysioAge Medical Group in 1997 in order to research and develop scientifically based personalized treatment programs focused on slowing the aging process. Since 1997, his Manhattan-based practice has been focused solely on age management medicine and assessing biomarkers of aging.

### **About AtCor Medical**

AtCor Medical develops and markets products for the early detection of arterial stiffness, target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures, and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor system, provides clinicians with better prognostic and diagnostic information to determine the need for, and type of, patient interventions, effects which cannot be detected with standard brachial cuff blood pressure measurements.

More than 4,000 SphygmoCor systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe.

*For further information, please contact:*  
**AtCor Medical**

Duncan Ross  
+1 (630) 228 8873

Peter Manley  
+61 (2) 8815 8811

*Media enquiries to:*  
**Financial & Corporate Relations**

Ashley Rambukwella  
Ph: +61 (2) 8264 1004/ m. 0407 231 282 or  
[a.rambukwella@fcr.com.au](mailto:a.rambukwella@fcr.com.au)